Impact News +++ AKTIONÄR-Hot-Stock Volex: Über 30 Prozent in knapp 4 Wochen – jetzt noch einsteigen? (Der Aktionaer) +++ VOLEX Aktie +3,01%

ASYMCHEM Aktie

>ASYMCHEM Aktienkurs

11.2 EUR +3.7% (TradegateBSX)

Ask: 11.6 EUR / 946 Stück

Bid: 11.2 EUR / 986 Stück

Tagesumsatz: 10 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ASYMCHEM Aktie über LYNX handeln

Intraday

1 Jahr

>ASYMCHEM Performance

1 Woche: +0,9%

1 Monat: +29,3%

3 Monate: +16,4%

6 Monate: +6,9%

1 Jahr: +83,1%

laufendes Jahr: +31,7%

>ASYMCHEM Aktie

Name:

ASYMCHEM LABORATORIES

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

CNE100004Z06 / A3C8W4

Symbol/ Ticker:

7K90 (Frankfurt)

Kürzel:

FRA:7K90, ETR:7K90, 7K90:GR

Index:

Webseite:

https://www.asymchem.com...

Profil:

Asymchem Laboratories (Tianjin) Co., Ltd. is a leading player in the contract research and manufacturing industry, with a focus on providing comprehensive drug development and manufacturing services. Established to support the pharmaceutical industry..
>Volltext..

Marktkapitalisierung:

4914.36 Mio. EUR

Unternehmenswert:

4050.2 Mio. EUR

Umsatz:

793.27 Mio. EUR

EBITDA:

191.68 Mio. EUR

Nettogewinn:

134.5 Mio. EUR

Gewinn je Aktie:

0.38 EUR

Schulden:

63.93 Mio. EUR

Liquide Mittel:

771.58 Mio. EUR

Operativer Cashflow:

192.36 Mio. EUR

Bargeldquote:

3.89

Umsatzwachstum:

1.2%

Gewinnwachstum:

4.94%

Dividende je Aktie:

0.13 EUR

Dividendenrendite:

1.31%

Dividendenschätzung:

1.67%

Div. Historie:

25.06.25 - 0.13276644€
13.06.24 - 0.21830642€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

ASYMCHEM

Letzte Datenerhebung:

27.04.26

>ASYMCHEM Kennzahlen

Aktien/ Unternehmen:

Aktien: 27.83 Mio. St.

Frei handelbar: 98.29%

Leerverk. Aktien: -

Rückkaufquote: 0.15%

Mitarbeiter: 10617

Umsatz/Mitarb.: 0.07 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 25.15%

Bewertung:

KGV: 28.32

KGV lG: 22.04

KUV: 5.19

KBV: 1.78

PEG-Ratio: 1.66

EV/EBITDA: 21.13

Rentabilität:

Bruttomarge: 40%

Gewinnmarge: 16.96%

Operative Marge: 15.55%

Managementeffizenz:

Gesamtkaprendite: 5.67%

Eigenkaprendite: 6.53%

>ASYMCHEM Peer Group

Gesundheit

>ASYMCHEM Chart & Kurs - Tradegate

>ASYMCHEM News

27.04.26 - 09:15	G Sachs: Mainland CDMO Sector Remains Resilient, Favors Wuxi AppTec , Asymchem and Others (AAStocks)
	G Sachs published a research report on the mainland pharmaceutical sector, stating that the results of CDMO companies reflect that the sectors cycle remains resilient. Earnings visibility is increasingly dependent on exposure to late-stage and commercialization projects rather than early-stage financing conditions. Artificial i......

14.04.26 - 15:33	Asymchem Unveils Its Fully Integrated TIDES Commercial Supply Matrix - Supporting Partners from Molecule to Market (PR Newswire)
	TIANJIN, China, April 14, 2026 /PRNewswire/ -- Asymchem, a global contract development and manufacturing organization (CDMO), has unveiled an integrated commercial supply matrix for TIDES (Peptides and Oligonucleotides) at its TJ4 site, combining expanded API manufacturing capacity,......

09.03.26 - 14:03

AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities (GlobeNewswire EN)

SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ /6821.HK), recently announced that its Fengxian commercial manufacturing site in Shanghai has officially commenced operations. This milestone completes a Shanghai-based “Golden Triangle” footprint comprising the Zhangjiang Science & Technology Center, Jinshan Site, and Fengxian Site. The three locations integrate end-to-end CDMO capabilities from early R&D and process development through clinical pilot-scale production, to commercial manufacturing, advancing client programs from IND to BLA through efficient cross-site coordination....

10.02.26 - 15:03	AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle (PR Newswire)
	SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the......

08.12.25 - 06:03	AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities (PR Newswire)
	SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- AsymBio, a technology-driven global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), today announced the official start of commercial production at its Shanghai Fengxian......

23.06.25 - 23:45	XFRA: DIVIDEND/INTEREST INFORMATION - 25.06.2025 - EQUBF_01 (XETRA)
	Das Instrument 7K90 CNE100004Z06 ASYMCHEM LAB.(TIAN.)H YC1 EQUITY wird cum Dividende/Zinsen gehandelt am 24.06.2025 und ex Dividende/Zinsen am 25.06.2025 The instrument 7K90 CNE100004Z06 ASYMCHEM LAB.(TIAN.)H YC1 EQUITY has its pre-dividend/interest day on 24.06.2025 and its ex-dividend/interest day on 25.06.2025...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das Gesetz ist nichts anderes als ein richtiges, von dem Wesen der Götter hergeleitetes Gebot der Vernunft, welches das, was ehrbar ist, gebietet, und das, was entgegensteht, verwehrt. - Marcus Tullius Cicero

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram